A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2016
At a glance
- Drugs FDL 169 (Primary) ; FDL 169
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Flatley Discovery Lab
- 21 Oct 2016 Status changed from recruiting to completed.
- 08 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
- 08 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.